What are the reported side effects of Mod-GRF(1-29)?

Reported side effects of Mod-GRF(1-29) include: Water retention (mild, dose-dependent), Tingling / numbness in extremities (carpal tunnel-like at high doses), Increased appetite (via GHRP component — less with Mod-GRF alone), Flushing or warmth at injection site, Transient fatigue post-injection.

Performance

Mod-GRF(1-29)

Q: What is the dosing range for Mod-GRF(1-29)?

Mod-GRF(1-29) is typically dosed at 100mcg (low), 100mcg (moderate), or 200mcg (high) mcg, administered 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking). These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

Also known as: Modified GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF, Sermorelin analog

Mod-GRF(1-29) is a research compound not approved for human use. For informational purposes only.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

Mod-GRF(1-29) is a stabilized analog of growth hormone-releasing hormone (GHRH) that spans residues 1–29 of the native peptide. Unlike CJC-1295 (which includes a Drug Affinity Complex for multi-day half-life), Mod-GRF(1-29) has a short ~30-minute active window — mimicking the natural GHRH pulse pattern. It is the preferred GHRH component for precise, pulsatile GH protocols when combined with a GHRP.

Research Summary

Native GHRH(1-29) is rapidly cleaved by plasma dipeptidyl peptidase IV (DPP-IV) within 2–3 minutes. Mod-GRF(1-29) incorporates four amino acid substitutions (positions 2, 8, 15, 27) that resist DPP-IV degradation, extending the half-life to approximately 30 minutes while preserving GHRH receptor binding affinity. This creates a half-life window aligned with physiological GH pulsatility, making it suitable for 2–3x daily injections that mimic natural GH release patterns.

Dosing Range

low

100mcg

moderate

100mcg

high

200mcg

Units: mcg · Frequency: 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking)

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Subcutaneous injectionIntramuscular injection

Reconstitution Notes

Reconstitute with bacteriostatic water. Common concentration: 2mg per 2mL BAC water (1mcg/µL). Always co-inject with a GHRP for synergistic GH release. Stable 28 days refrigerated.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Water retention (mild, dose-dependent)
Tingling / numbness in extremities (carpal tunnel-like at high doses)
Increased appetite (via GHRP component — less with Mod-GRF alone)
Flushing or warmth at injection site
Transient fatigue post-injection

Research Papers

2 peer-reviewed sources

Modified GRF(1-29) analogues with improved resistance to degradation

Journal of Medicinal Chemistry1996

Synergistic release of growth hormone by GHRH and GHRP combinations

Journal of Clinical Endocrinology & Metabolism1997

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Peptides

Community protocols combining Mod-GRF(1-29) with Ipamorelin or GHRP-2 for pulsatile GH optimization.

View original thread

Overview

Mod-GRF(1-29) — often labeled "CJC-1295 without DAC" by research suppliers — is a GHRH analog that occupies the GHRH receptor to amplify the height of each GH pulse. Its ~30-minute half-life is intentional: it mirrors the way endogenous GHRH pulses are delivered, preserving the natural on/off rhythm of the GH axis.

Mod-GRF vs CJC-1295: Understanding the Difference

This distinction is widely misunderstood in research communities:

| | Mod-GRF(1-29) | CJC-1295 (with DAC) | |-|---------------|---------------------| | Half-life | ~30 minutes | 6–8 days | | Mechanism | Pulse-matched GHRH release | Sustained GHRH elevation | | GH pattern | Pulsatile (physiological) | Blunted pulses, elevated baseline | | Dosing | 2–3x daily | Once weekly | | Preferred for | Natural GH axis mimicry | Convenience |

Most serious GH optimization protocols prefer Mod-GRF(1-29) for its preservation of the pulsatile GH pattern — thought to be important for maintaining receptor sensitivity and IGF-1 rhythm.

The GHRH + GHRP Synergy

Mod-GRF(1-29) is almost always co-administered with a GHRP (Ipamorelin, GHRP-2, or GHRP-6). The combination is synergistic rather than additive:

GHRH (Mod-GRF): Elevates the amplitude ceiling of the GH pulse
GHRP: Triggers the timing of the GH pulse and blocks somatostatin

Studies show the combination produces GH pulses 4–10x larger than either compound alone.

Standard Protocol

Most common research protocol:

100mcg Mod-GRF(1-29) + 100–200mcg Ipamorelin, co-injected subcutaneously
Timing: 30 minutes before sleep (most important injection for recovery), optionally pre-workout
Do not eat 30–60 minutes before or after injection (insulin blunts GH release)
Cycle: 12–16 weeks on, 4 weeks off